Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sepracor Plans April 4 Lunesta Launch

This article was originally published in The Pink Sheet Daily

Executive Summary

Sepracor will launch the insomnia agent upon same-day publication of the final rule designating Lunesta as a Schedule IV controlled substance. More than 40,000 retail pharmacies already have placed orders for eszopiclone, the company says.
Advertisement

Related Content

GSK Gains EU Rights To Lunesta Through Deal With Sepracor
GSK Gains EU Rights To Lunesta Through Deal With Sepracor
Sepracor Signs Agreement With Eisai To Market Lunesta In Japan
Sepracor's "Product And Use" Lunesta Ad To Be "Very Visible," Company Says
Sepracor Insomnia Spot Suggests Lunesta “Product And Use” Ads Coming Soon
Lunesta Schedule IV Placement Effective Immediately, DEA Says
Sanofi Not "Desperate" To Improve Ambien Label In Face Of Competition
Lunesta Scripts Limited To Five Refills Under Proposed DEA Scheduling
Lunesta Scripts Limited To Five Refills Under Proposed DEA Scheduling
Sepracor Insomnia Agent Lunesta Priced At Premuim To Ambien

Topics

Advertisement
UsernamePublicRestriction

Register

PS061943

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel